专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20050186205A1 Therapeutic application of chimeric and radiolabeled antibodies to human B Lymphocyte restricted differentiation antigen for treatment of B cell Lymphoma 审中-公开
标题翻译：嵌合和放射性标记抗体对人B的治疗应用淋巴细胞限制性分化抗原治疗B细胞淋巴瘤
公开(公告)号：US20050186205A1
公开(公告)日：2005-08-25
申请号：US10956039
申请日：2004-10-04
申请人： Darrell Anderson , Nabil Hanna , John Leonard , Roland Newman , Mitchell Reff , William Rastetter
发明人： Darrell Anderson , Nabil Hanna , John Leonard , Roland Newman , Mitchell Reff , William Rastetter
IPC分类号： C12N15/02 , A61K31/375 , A61K31/573 , A61K31/664 , A61K31/704 , A61K38/00 , A61K39/395 , A61K45/00 , A61K47/48 , A61K51/00 , A61K51/08 , A61K51/10 , A61P35/00 , C07K16/28 , C07K16/46 , C12N1/21 , C12N5/02 , C12N5/10 , C12N15/09 , C12P21/02 , C12P21/08 , C12R1/91 , G01N33/53 , A61K31/4745 , A61K31/66
CPC分类号： C07K16/2887 , A61K38/00 , A61K47/6849 , A61K51/1027 , A61K51/1093 , A61K2039/505 , C07K2317/24 , C07K2317/56 , C07K2317/732 , C07K2319/00 , C12N2799/028 , Y10S424/80 , Y10S424/801 , Y10S530/808 , Y10S530/809 , Y10S530/867
摘要： Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chim eric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, and cooperative strategies comprising the use of chimeric anti-CD20 antibodies and radiolabeled anti-CD20 antibodies.
摘要翻译：本文公开了设计用于治疗B细胞淋巴瘤的治疗方案。这些方案基于治疗策略，其包括使用免疫活性的小鼠/人中性抗CD20抗体的施用，放射性标记的抗CD20抗体，以及包括使用嵌合抗CD20抗体和放射性标记的抗CD20抗体的协同策略。

2. 发明申请

US20080089893A9 THERAPEUTIC APPLICATION OF CHIMERIC AND RADIOLABELLED ANTIBODIES TO HUMAN B LYMPHOCYTE RESTRICTED DIFFERENTIATION ANTIGEN FOR TREATMENT OF B CELL LYMPHOMA 失效
标题翻译：用于治疗B细胞淋巴瘤的人B淋巴细胞限制性差异抗原的化疗和放射免疫抗体的治疗应用
公开(公告)号：US20080089893A9
公开(公告)日：2008-04-17
申请号：US09911703
申请日：2001-07-25
申请人： Darrell Anderson , Nabil hanna , Ronald Newman , Mitchell Reff , William Rastetter
发明人： Darrell Anderson , Nabil hanna , Ronald Newman , Mitchell Reff , William Rastetter
IPC分类号： A61K39/395
CPC分类号： C07K16/2887 , A61K38/00 , A61K47/6849 , A61K51/1027 , A61K51/1093 , A61K2039/505 , C07K2317/24 , C07K2317/56 , C07K2317/732 , C07K2319/00 , C12N2799/028 , Y10S424/80 , Y10S424/801 , Y10S530/808 , Y10S530/809 , Y10S530/867
摘要： Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, and cooperative strategies comprising the use of chimeric anti-CD20 antibodies and radiolabeled anti-CD20 antibodies.
摘要翻译：本文公开了设计用于治疗B细胞淋巴瘤的治疗方案。这些方案基于治疗策略，其包括使用免疫活性的小鼠/人嵌合抗CD20抗体，放射性标记的抗CD20抗体和合作策略

3. 发明申请

US20080095769A1 IDENTIFICATION OF UNIQUE BINDING INTERACTIONS BETWEEN CERTAIN ANTIBODIES AND THE HUMAN B7.1 AND B7.2 CO-STIMULATORY ANTIGENS 失效
公开(公告)号：US20080095769A1
公开(公告)日：2008-04-24
申请号：US11840591
申请日：2007-08-17
申请人： Darrell Anderson , Nabil Hanna , Peter Brams
发明人： Darrell Anderson , Nabil Hanna , Peter Brams
IPC分类号： A61K39/395 , A61P31/00 , A61P37/00 , C07K16/18 , C07K16/28
CPC分类号： C07K16/2827 , A61K2039/505 , C07K2317/24 , C07K2317/55 , C07K2317/73 , C07K2317/76 , C07K2317/92
摘要： The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 receptor. Two of these antibodies, 16C10 and 7C10, significantly inhibit the production of IL-2, in spite of the existence of a second activating ligand B7.2 (CD86). Blocking of the primary activation signal between CD28 and B7.1 (CD80) with these antibodies while allowing the unimpaired or coincident interaction of CTLA-4 and B7.1 and/or B7.2 represents a combined antagonistic effect on positive co-stimulation with an agonistic effect on negative signalling. These antibodies may be used as specific immunosuppressants, e.g., for the treatment of autoimmune diseases and to prevent organ transplant rejection.

4. 发明申请

US20060275291A1 Identification of Unique Binding Interactions Between Certain Antibodies and the Human B7.1 and B7.2 Co-Stimulatory Antigens 有权
标题翻译：鉴定某些抗体与人B7.1和B7.2共刺激抗原之间的独特结合相互作用
公开(公告)号：US20060275291A1
公开(公告)日：2006-12-07
申请号：US11464133
申请日：2006-08-11
申请人： Darrell Anderson , Nabil Hanna , Peter Brams
发明人： Darrell Anderson , Nabil Hanna , Peter Brams
IPC分类号： A61K39/395 , C07K16/28
CPC分类号： C07K16/2827 , A61K2039/505 , C07K2317/24 , C07K2317/55 , C07K2317/73 , C07K2317/76 , C07K2317/92
摘要： The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 receptor. Two of these antibodies, 16C10 and 7C10, significantly inhibit the production of IL-2, in spite of the existence of a second activating ligand B7.2 (CD86). Blocking of the primary activation signal between CD28 and B7.1 (CD80) with these antibodies while allowing the unimpaired or coincident interaction of CTLA-4 and B7.1 and/or B7.2 represents a combined antagonistic effect on positive co-stimulation with an agonistic effect on negative signalling. These antibodies may be used as specific immunosuppressants, e.g., for the treatment of autoimmune diseases and to prevent organ transplant rejection.
摘要翻译：本发明涉及对人B7.1抗原（CD80）特异性并且能够抑制B7.1与CD28受体的结合并且不能抑制B7.1结合的抗体的鉴定到CTLA-4受体。尽管存在第二活化配体B7.2（CD86），但是这些抗体16C10和7C10中的两个显着抑制了IL-2的产生。阻断CD28和B7.1（CD80）之间的主要激活信号与这些抗体同时允许CTLA-4和B7.1和/或B7.2的未受损或一致的相互作用代表对阳性共刺激的组合拮抗作用，对负信号的激动作用。这些抗体可以用作特异性免疫抑制剂，例如用于治疗自身免疫性疾病和预防器官移植排斥。

5. 发明申请

US20050129688A1 Monkey monoclonal antibodies specific to human B7.1 and/or B7.2 primatized forms thereof, pharmaceutical compositions containing, and use thereof as immunosuppressants 有权
标题翻译：针对人B7.1和/或B7.2的灵长类形式的特异性猴单克隆抗体，含有其的药物组合物及其作为免疫抑制剂的用途
公开(公告)号：US20050129688A1
公开(公告)日：2005-06-16
申请号：US10986780
申请日：2004-11-15
申请人： Darrell Anderson , Peter Brams , Nabil Hanna , William Shestowsky , Cheryl Heard
发明人： Darrell Anderson , Peter Brams , Nabil Hanna , William Shestowsky , Cheryl Heard
IPC分类号： C12N15/02 , A61K38/00 , A61K39/395 , A61P17/00 , A61P29/00 , A61P35/00 , A61P37/00 , C07K14/705 , C07K16/18 , C07K16/28 , C12N5/10 , C12N15/09 , C12P21/08 , C07K16/44 , C12N5/06
CPC分类号： C07K14/70532 , A61K38/00 , C07K16/2827
摘要： The present invention relates to the identification of macaque antibodies to human B7.1 and B7.2 by screening of phage display libraries or monkey heterohybridomas obtained using B lymphocytes from B7.1 and/or B7.2 immunized monkeys. More specifically, the invention provides four monkey monoclonal antibodies 7B6, 16C10, 7C10 and 20C9 which inhibit the B7:CD28 pathway and thereby function as effective immunosuppressants. The invention further provides the complete DNA and amino acid sequences of the light and heavy chain of three primatized antibodies derived from those monkey monoclonal antibodies which bind B7.1 and possibly B7.2, primatized 7C10, primatized 7B6 and primatized 16C10. These primatized and monkey antibodies may be used as specific immunosuppressants, e.g., for the treatment of autoimmune diseases and to prevent organ transplant rejection.
摘要翻译：本发明涉及通过筛选使用B7.1和/或B7.2免疫的猴子的B淋巴细胞获得的噬菌体展示文库或猴杂合杂交瘤来鉴定人B7.1和B7.2的猕猴抗体。更具体地，本发明提供四种抑制B7：CD28途径的猴单克隆抗体7B6,16C10,7C10和20C9，从而起到有效的免疫抑制剂的作用。本发明进一步提供衍生自结合B7.1和可能B7.2，灵长类化7C10，灵长类化7B6和灵长类16C10的猴单克隆抗体的三种灵长类抗体轻链和重链的完整DNA和氨基酸序列。这些灵长类和猴抗体可以用作特异性免疫抑制剂，例如用于治疗自身免疫性疾病和预防器官移植排斥。

6. 发明申请

US20070128185A1 IDENTIFICATION OF UNIQUE BINDING INTERACTIONS BETWEEN CERTAIN ANTIBODIES AND THE HUMAN B7.1 AND B7.2 CO-STIMULATORY ANTIGENS 失效
标题翻译：识别某些抗体与人B7.1和B7.2共刺激抗原之间的独特结合相互作用
公开(公告)号：US20070128185A1
公开(公告)日：2007-06-07
申请号：US11553302
申请日：2006-10-26
申请人： Darrell Anderson , Nabil Hanna , Peter Brams
发明人： Darrell Anderson , Nabil Hanna , Peter Brams
IPC分类号： A61K39/395 , C07K16/28
CPC分类号： C07K16/00 , A61K38/00 , A61K2039/505 , C07K14/70532 , C07K16/2827 , C07K2317/21 , C07K2317/55 , C07K2317/76 , C07K2317/92
摘要： The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 receptor. Two of these antibodies, 16C10 and 7C10, significantly inhibit the production of IL-2, in spite of the existence of a second activating ligand B7.2 (CD86). Blocking of the primary activation signal between CD28 and B7.1 (CD80) with these antibodies while allowing the unimpaired or coincident interaction of CTLA-I and b7.1 and/or B7.2 represents a combined antagonistic effect on positive co-stimulation with an agonistic effect on negative signalling. These antibodies may be used as specific immunosuppressants, e.g., for the treatment of autoimmune diseases and to prevent organ transplant rejection.
摘要翻译：本发明涉及对人B7.1抗原（CD80）特异性并且能够抑制B7.1与CD28受体的结合并且不能抑制B7.1结合的抗体的鉴定到CTLA-4受体。尽管存在第二活化配体B7.2（CD86），但是这些抗体16C10和7C10中的两个显着抑制了IL-2的产生。使用这些抗体阻断CD28和B7.1（CD80）之间的主要激活信号，同时允许CTLA-1和b7.1和/或B7.2的未受损或一致的相互作用代表对阳性共刺激的组合拮抗作用，对负信号的激动作用。这些抗体可以用作特异性免疫抑制剂，例如用于治疗自身免疫性疾病和预防器官移植排斥。

7. 发明申请

US20050260205A1 Identification of unique binding interactions between certain antibodies and the human B7.1 and B7.2 co-stimulatory antigens and therapy thereof 有权
标题翻译：鉴定某些抗体与人B7.1和B7.2共刺激抗原之间的独特结合相互作用及其治疗
公开(公告)号：US20050260205A1
公开(公告)日：2005-11-24
申请号：US11139499
申请日：2005-05-31
申请人： Darrell Anderson , Nabil Hanna , Peter Brams
发明人： Darrell Anderson , Nabil Hanna , Peter Brams
IPC分类号： A61K39/395 , C07K16/12 , C07K16/24 , C07K16/28
CPC分类号： C07K16/2827 , A61K2039/505 , C07K2317/24 , C07K2317/55 , C07K2317/73 , C07K2317/76 , C07K2317/92
摘要： The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 receptor. Two of these antibodies, 16C10 and 7C10, significantly inhibit the production of IL-2, in spite of the existence of a second activating ligand B7.2 (CD86). Blocking of the primary activation signal between CD28 and B7.1 (CD80) with these antibodies while allowing the unimpaired or coincident interaction of CTLA-4 and B7.1 and/or B7.2 represents a combined antagonistic effect on positive co-stimulation with an agonistic effect on negative signaling. These antibodies or B7.1-binding fragments thereof, may be used for the treatment or prevention of resistance to or rejection of transplanted organs or tissues and/or graft-versus-host diseases.
摘要翻译：本发明涉及对人B7.1抗原（CD80）特异性并且能够抑制B7.1与CD28受体的结合并且不能抑制B7.1结合的抗体的鉴定到CTLA-4受体。尽管存在第二活化配体B7.2（CD86），但是这些抗体16C10和7C10中的两个显着抑制了IL-2的产生。阻断CD28和B7.1（CD80）之间的主要激活信号与这些抗体同时允许CTLA-4和B7.1和/或B7.2的未受损或一致的相互作用代表对阳性共刺激的组合拮抗作用，对负信号的激动作用。这些抗体或其B7.1结合片段可用于治疗或预防移植的器官或组织和/或移植物抗宿主病的抗性或排斥反应。

8. 发明授权

US06614764B1 Bridged network topology acquisition 有权
标题翻译：桥接网络拓扑采集
公开(公告)号：US06614764B1
公开(公告)日：2003-09-02
申请号：US09496294
申请日：2000-02-01
申请人： Thomas L. Rodeheffer , Darrell Anderson , Chandramohan A. Thekkath , Mark D. Lillibridge
发明人： Thomas L. Rodeheffer , Darrell Anderson , Chandramohan A. Thekkath , Mark D. Lillibridge
IPC分类号： H04J1500
CPC分类号： H04L45/02 , H04L12/462 , H04L41/12 , H04L45/04
摘要： A bridged network and a method for performing bridged network topology acquisition. The bridged network includes network segments and smart bridges having one or more ports. The network segments are interconnected by the smart bridges via the ports. Each of the smart bridges being configured to perform steps to accomplish the network topology acquisition. The method also performs steps to accomplish the network topology acquisition. The steps include an inventory construction that compiles a list of the ports that are connected to each of the network segments. Among the ports that are connected to any of the network segments the inventory construction respecting each port operates cooperatively so as to cause the list respecting each of the ports to converge rapidly to the state in which all the lists are similar and yielding a uniform segment inventory. The bridged network topology acquisition in each of the smart bridges operates cooperatively with the bridged network topology acquisition in other smart bridges in order to create a total network report from most recent segment inventories. The bridged network topology acquisition includes propagation, collection, and distribution. The bridges network topology acquisition affords better management of network topology changes.
摘要翻译：一种桥接网络和一种执行桥接网络拓扑采集的方法。桥接网络包括具有一个或多个端口的网段和智能桥。网段通过智能桥经由端口互连。每个智能桥被配置为执行完成网络拓扑获取的步骤。该方法还执行完成网络拓扑采集的步骤。这些步骤包括编制连接到每个网段的端口的列表的库存结构。在连接到任何网段的端口中，关于每个端口的库存结构协同工作，以使得关于每个端口的列表快速收敛到所有列表相似的状态并产生统一的段库存。每个智能桥中的桥接网络拓扑采集与其他智能桥中的桥接网络拓扑采集协同工作，以便创建来自最近段段清单的总网络报告。桥接网络拓扑采集包括传播，收集和分发。网桥拓扑收集可以更好地管理网络拓扑变化。

9. 发明授权

US08504551B2 Serving advertisements based on content 有权
公开(公告)号：US08504551B2
公开(公告)日：2013-08-06
申请号：US13084332
申请日：2011-04-11
申请人： Darrell Anderson , Paul Buchheit , Alexander Paul Carobus , Yingwei Cui , Jeffrey A. Dean , Georges R. Harik , Deepak Jindal , Narayanan Shivakumar
发明人： Darrell Anderson , Paul Buchheit , Alexander Paul Carobus , Yingwei Cui , Jeffrey A. Dean , Georges R. Harik , Deepak Jindal , Narayanan Shivakumar
IPC分类号： G06F17/30
CPC分类号： G06F17/30864 , G06F17/30454 , G06Q30/02 , G06Q30/0251 , Y10S707/944 , Y10S707/99945 , Y10S707/99948
摘要： Advertisers are permitted to put targeted ads on page on the web (or some other document of any media type). The present invention may do so by (i) obtaining content that includes available spots for ads, (ii) determining ads relevant to content, and/or (iii) combining content with ads determined to be relevant to the content.

10. 发明授权

US08090951B2 Systems and methods for transparent configuration authentication of networked devices 有权
标题翻译：网络设备透明配置认证的系统和方法
公开(公告)号：US08090951B2
公开(公告)日：2012-01-03
申请号：US10627270
申请日：2003-07-25
申请人： Úlfar Erlingsson , Xavier Boyen , Darrell Anderson , Wayne Gray
发明人： Úlfar Erlingsson , Xavier Boyen , Darrell Anderson , Wayne Gray
IPC分类号： H04L9/32
CPC分类号： H04L63/12 , G06F21/10 , G06F21/60 , G06Q20/401 , H04L63/08 , H04L63/123 , H04L63/20 , H04L2209/608 , H04N1/32144 , H04N21/8358
摘要： Methods and systems are disclosed for providing secure transmissions across a network comprising a transmitting device and a receiving device. At the transmitting device, a stream of watermark bits is generated. Next, a plurality of watermarks is generated, each of the plurality of watermarks comprising an index number and a portion of the stream of watermark bits. The watermarks are inserted into each header of a plurality of outgoing packets. At the receiving device, the plurality of outgoing packets are received and it is determined if a received packet is valid based on the watermark in the header of the received packet. The stream of watermark bits may be generated using a stream cipher such as RC4, a block cipher such as 3DES in CBC mode, or other equivalent pseudo-random stream generating techniques.
摘要翻译：公开了用于通过包括发射设备和接收设备的网络提供安全传输的方法和系统。在发送装置，生成水印比特流。接下来，生成多个水印，多个水印中的每一个包括索引号和水印比特流的一部分。水印被插入到多个输出分组的每个报头中。在接收装置中，接收多个输出分组，并且基于接收分组的报头中的水印确定接收到的分组是否有效。可以使用诸如RC4的流密码，CBC模式中的诸如3DES的块密码或其他等效的伪随机流生成技术来生成水印比特流。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式